

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

021660Orig1s029

Trade Name: ABRAAXANE for Injectable Suspension

Generic or Proper Name: paclitaxel protein-bound particles for injectable suspension (albumin-bound)

Sponsor: Celgene Corporation

Approval Date: December 23, 2011

Indication: For the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or replete within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

CENTER FOR DRUG EVALUATION AND RESEARCH

021660Orig1s029

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Summary Review	
Officer/Employee List	
Office Director Memo	
Cross Discipline Team Leader Review	
Medical Review(s)	
Chemistry Review(s)	
Environmental Assessment	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology / Virology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

021660Orig1s029

APPROVAL LETTER



NDA 021660/S-025
NDA 021660/S-026
NDA 021660/S-029

SUPPLEMENT APPROVAL

Celgene Corporation
Attention: Renu Vaish, M.S.
Executive Director, Global Regulatory Affairs
Therapeutic Franchise Leader - Oncology Solid Tumors
400 Connell Drive, Suite 7000
Berkeley Heights, NJ 07922

Dear Ms. Vaish:

Please refer to your Supplemental New Drug Applications (sNDA) dated March 30, 2010, received March 30, 2010, June 1, 2010, received June 2, 2010, and July 25, 2011, received July 25, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), 100 milligram vial.

We acknowledge receipt of your amendments dated December 8, 2010; February 25, 2011; July 8, 2011; August 26, 2011; August 30, 2011; September 1, 2011; September 6, 2011; September 8 (2), 2011; September 13, 2011; September 14, 2011; September 21, 2011, December 5, 2011; December 20, 2011, and December 22 (2), 2011.

“Prior Approval” supplemental new drug application (S-025) provides for inclusion of pyrexia, dehydration, pancytopenia, congestive heart failure, and left ventricular dysfunction in Section 6, ADVERSE REACTIONS of the Package Insert.

“Prior Approval” supplemental new drug application (S-026) provides for revised labeling in the Physician Labeling Rule format.

“Prior Approval” supplemental new drug application (S-029) provides for inclusion of three adverse events: Stevens-Johnson syndrome, toxic epidermal necrolysis and extravasation in Section 6, ADVERSE REACTIONS of the Package Insert and minor administrative, editorial and grammatical revisions throughout the Package Insert.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.